News

ABEC announced it will design, manufacture, and install multiple 4,000L fermenter trains for HEC Pharm’s manufacturing site in Guangzhou, China. The stainless-steel fermenter trains are…
Read More...

Sanofi announced a €400 million investment over five years to create a unique vaccine production center in Singapore, pushing the boundaries of operations through cutting edge…
Read More...

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory…
Read More...

Thermo Fisher Scientific Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the Thermo Fisher Scientific Amplitude…
Read More...

Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class…
Read More...

CanSino Biologics Inc. announced that the Instituto de Salud Pública de Chile granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5…
Read More...

Biogen Inc. and Bio-Thera Solutions, Ltd. announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3…
Read More...

Sanofi acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology…
Read More...

Celcuity Inc. a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced it has entered…
Read More...

Eli Lilly and Company and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial…
Read More...

Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and…
Read More...

AbbVie announced that it has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for SKYRIZI …
Read More...

Icosavax, Inc. announced the close of a $100 million Series B Financing, led by RA Capital Management and joined by Janus Henderson Investors, Perceptive Advisors, Viking Global…
Read More...

CytoDyn Inc. a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced it has executed an…
Read More...

AIM ImmunoTech Inc. announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious…
Read More...

AB Science SA together with the University of Chicago, announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans…
Read More...

Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for…
Read More...

Progenity, Inc. a biotechnology company with an established track record of success developing and commercializing molecular testing products, announced an agreement with Ionis…
Read More...

MyBiotics Pharma Ltd., a microbiome therapeutics company, and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center,…
Read More...

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced…
Read More...